People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotechnology, Pharmaceuticals, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Scorpion Therapeutics, Inc. | — | Biotechnology | Series D+ | $297.4M | $1.4B | 2024 |
| Triana Biomedicines, Inc. | — | Pharmaceuticals | Series D+ | $178.6M | $852.1M | 2022 |
| Seismic Therapeutic, Inc. | — | Biotech / Pharma | Series D+ | $146.3M | $1.9B | 2023 |
| Enlaza Therapeutics, Inc. | — | Pharmaceuticals | Series C | $134.6M | $87.6M | 2021 |
| Protego Biopharma | — | Biotechnology | Series C | $85.0M | $179.2M | 2021 |
| Antares Therapeutics, Inc. | — | Biotechnology | Series B | $70.0M | $149.6M | 2025 |
| Abata Therapeutics, Inc. | — | Biotechnology | Series C | $60.3M | $168.4M | 2021 |
| IFM Cinque, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2019 |
| IFM Quattro, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2019 |
| IFM Continua, Inc. | — | Biotechnology | Pre-Seed | $350K | $19.3M | 2019 |
Shelley Chu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shelley Chu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 5 | 17 |
| Gary Glick | 4 | 7 |
| John Leonard | 3 | 4 |
| Adam Friedman | 2 | 6 |
| Andrew Hedin | 2 | 5 |
| Keith Flaherty | 2 | 5 |
| Lorence Kim | 2 | 5 |
| Jeffrey Albers | 2 | 3 |
| Brian Piper | 2 | 2 |
| Andrew Fedder | 2 | 2 |
| ANDREW LEVIN | 1 | 17 |
| Joshua Resnick | 1 | 12 |
| James Topper | 1 | 12 |
| Alan Crane | 1 | 9 |
| Christopher O'Donnell | 1 | 8 |
| Stephen Squinto | 1 | 8 |
| Tighe Reardon | 1 | 7 |
| Jay Lichter | 1 | 7 |
| David Kaufman | 1 | 7 |
| David Grayzel | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.